Inflammatory Bowel Disease

Inflammatory Bowel Disease Content

Increased infliximab clearance in patients hospitalized with severe ulcerative colitis may lead to underexposure

New research has shown that infliximab clearance is increased in patients hospitalized with severe ulcerative colitis, potentially leading to a higher risk of underexposure when standard dosing regimens are used. The study, which analyzed infliximab pharmacokinetics in 154 patients with ulcerative colitis, found that patients who were hospitalized exhibited a 35% increase in infliximab clearance compared to outpatients (0.463 L/day vs. 0.339 L/day, p<0.0001). This resulted in subtherapeutic drug levels in the majority of patients from week 2 onwards, with 74% of hospitalized patients having infliximab concentrations below 20 µg/mL at week 2, 69% below 15 µg/mL at week 6, and 56% below 7 µg/mL at week 14.

Study finds comparable cardiovascular risk between JAKi and anti-TNFs in IBD

Research presented at the ACG 2024 Annual Scientific Meeting found no increased risk of major adverse cardiovascular events (MACE) or venous thromboembolism (VTE) in patients with inflammatory bowel disease (IBD) treated with Janus kinase inhibitors (JAKi) compared to those receiving anti-tumor necrosis factor (anti-TNF) therapy. This retrospective cohort study, led by Dr. Saqr Alsakarneh, analyzed data from 7,480 adult patients, showing comparable MACE and VTE rates across both treatment groups, even in older adults. These findings provide reassurance regarding the cardiovascular safety of JAKi in managing IBD, although further prospective studies are needed to validate long-term outcomes.

Digestive Disorders, Inflammatory Bowel Disease

Highlights from Digestive Disease Week 2023: Gil Y. Melmed

Watch Time: 5 mins

Digestive Disease Week took place between 6-9 May, in this touchIMMUNOLOGY interview, we caught up with our Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around his personal highlights from this year’s conference including non-pivotal clinical trial data analysing established inflammatory bowel disease (IBD) therapies such as vedolizumab, data around the […]

Digestive Disorders, Inflammatory Bowel Disease

Comparison study of upadacitinib and tofacitinib as induction treatment in ulcerative colitis: Gil Y. Melmed, DDW 2023

Watch Time: 5 mins

Upadacitinib and tofacitinib are both JAK inhibitors (JAKis) approved by the FDA for the treatment of ulcerative colitis. In this interview with Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) we discuss the aims, design and findings from his study presented at DDW 2023, comparing the efficacy and safety of these […]

Digestive Disorders, Inflammatory Bowel Disease

QUASAR: phase 3 study of guselkumab in moderately to severely active ulcerative colitis: Jessica Allegretti, DDW 2023

Watch Time: 4 mins

The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]

Digestive Disorders, Inflammatory Bowel Disease

Guselkumab: an investigational monoclonal antibody for ulcerative colitis: Jessica Allegretti, DDW 2023

Watch Time: 1 min

Guselkumab is a fully human monoclonal antibody IL-23 p19 subunit antagonist currently being investigated in hard to treat, moderately to severely active ulcerative colitis. We were delighted to speak with Dr Jessica Allegretti, (Brigham and Women’s Hospital, Boston, MA, USA) around the burden of ulcerative colitis in patients with inadequate response to currently approved treatments, […]

Inflammatory Bowel Disease

World IBD Day: From diagnosis and treatment options, to emerging research and the power of self-care!

Professor Ailsa Hart (St Mark’s Hospital, London, UK) joined touchIME on World IBD Day and discussed how diagnosis can be challenging, but emerging treatments can improve outcomes for people living with Crohn’s disease or ulcerative colitis. She also highlighted the impact that IBD can have on quality of life, including mental health and the […]

Inflammatory Bowel Disease

Simeng Lin, ECCO’23: Primary non-response to anti-TNF treatment in Crohn’s disease – an analysis of the PANTS study

Watch Time: 4 mins

The Personalised Anti-TNF Therapy in Crohn’s disease (PANTS) study was a UK-wide study that looked at anti-TNF treatment failure in Crohn’s disease. touchIMMUNOLOGY were delighted to speak with Simeng Lin (University of Exeter Medical School, Exeter, UK) to discuss the association between DNA methylation and primary non-response to anti-TNF treatment and the impact this will have […]

Inflammatory Bowel Disease

Simeng Lin, ECCO’23: Anti-TNF treatment failure in Crohn’s disease

Watch Time: 3 mins

Anti-TNF therapy is a mainstay of treatment for Crohn’s disease although treatment failure in patients with IBD is common. touchIMMUNOLOGY were delighted to speak with Simeng Lin (University of Exeter Medical School, Exeter, UK) to discuss the current standard of care for Crohn’s disease, anti-TNF therapy and factors thought to predict non-response to anti-TNF treatment. […]

Feedback

Feedback

FILTER YOUR SEARCH

Content Type:

Speciality:

Conference:

Inflammatory Bowel Disease